Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography.
Rankin S, Fountain C, Gemmell AJ, Quinn D, Henderson A, McClure J, Small S, Venugopal B, McKay P, Slomka PJ, Colville D, Petrie MC, Meléndez GC, Lang NN. Rankin S, et al. Among authors: venugopal b. bioRxiv [Preprint]. 2024 Jun 3:2024.05.30.596741. doi: 10.1101/2024.05.30.596741. bioRxiv. 2024. Update in: Clin Sci (Lond). 2025 Jan 15;139(1):29-41. doi: 10.1042/CS20241529. PMID: 38895275 Free PMC article. Updated. Preprint.
Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging.
Dobbin SJH, Mangion K, Berry C, Roditi G, Basak S, McClure JD, Brooksbank K, Sonecki P, Sourbron S, Evans J, White J, Welsh P, Butler E, Venugopal B, Touyz RM, Jones RJ, Petrie MC, Lang NN. Dobbin SJH, et al. Among authors: venugopal b. Heart. 2025 Apr 3:heartjnl-2024-325535. doi: 10.1136/heartjnl-2024-325535. Online ahead of print. Heart. 2025. PMID: 40180444 Free article.
What is required to deliver practice-changing neoadjuvant trials in kidney cancer? An International Neoadjuvant Kidney Cancer Consortium Delphi study.
Rossi SH, Choueiri TK, Jewett M, Jones JO, Laird A, Lewis B, Tippu Z, Van Der Mijn JCK, Bex A, Stewart GD; International Neoadjuvant Kidney Cancer Consortium (INKCC) members. Rossi SH, et al. Ann Oncol. 2025 Jun 4:S0923-7534(25)00769-0. doi: 10.1016/j.annonc.2025.05.540. Online ahead of print. Ann Oncol. 2025. PMID: 40480551 No abstract available.
Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus.
Wray R, Paverd H, Machado I, Barbieri J, Easita F, Edwards AR, Gallagher FA, Mendichovszky IA, Mitchell TJ, de la Roche M, Shields JD, Ursprung S, Wallis L, Warren AY, Welsh SJ, Crispin-Ortuzar M, Stewart GD, Jones JO; NAXIVA Study Group. Wray R, et al. Nat Commun. 2025 Apr 28;16(1):3870. doi: 10.1038/s41467-025-58436-8. Nat Commun. 2025. PMID: 40295487 Free PMC article.
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.
Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B. Powles T, et al. Among authors: venugopal b. Lancet Oncol. 2025 Apr;26(4):491-502. doi: 10.1016/S1470-2045(25)00032-4. Epub 2025 Mar 17. Lancet Oncol. 2025. PMID: 40112850 Clinical Trial.
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Leone G, Orlando F, Dutey-Magni P, Vainauskas O, Grist E, Ciani Y, Lall S, Thakali S, Wingate A, Wetterskog D, Sachdeva A, Sydes MR, McPhail N, Sreenivasan T, O'Sullivan JM, Clarke NW, Parmar MKB, Brown LC, James ND, Demichelis F, Attard G; STAMPEDE collaborators. Leone G, et al. JAMA Oncol. 2025 Feb 27;11(4):426-9. doi: 10.1001/jamaoncol.2024.7051. Online ahead of print. JAMA Oncol. 2025. PMID: 40014335
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.
Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juárez V, Rini BI, Larkin J, Nolè F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ. Choueiri TK, et al. Among authors: venugopal b. Ann Oncol. 2025 Apr;36(4):387-392. doi: 10.1016/j.annonc.2024.12.008. Epub 2024 Dec 18. Ann Oncol. 2025. PMID: 39706335 Free article. Clinical Trial.
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF Jr, Venugopal B, Woo HH, Ramirez-Backhaus M, Tarazi J, Tang Y, Ganguli A, Haas GP, Shore ND. Freedland SJ, et al. Among authors: venugopal b. Future Oncol. 2025 Feb;21(5):501-514. doi: 10.1080/14796694.2024.2426425. Epub 2024 Dec 12. Future Oncol. 2025. PMID: 39667819 Free PMC article.
113 results